Related Experiment Video
Updated: Apr 27, 2026
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Update on the development of enterovirus 71 vaccines
Yu-An Kung1, Chuan-Tien Hung, Yen-Chin Liu
1Chang Gung University, Research Center for Emerging Viral Infections , 259 Wen-Hua 1st Road, Kwei-Shan, Taoyuan, 333 (Zip code) , Taiwan +886 3 2118800 ext. 5497 ; +886 3 2118174 ; srshih@mail.cgu.edu.tw.
Introduction:
Enterovirus 71 (EV71) is an etiological agent that causes severe neurological complications in children. EV71 outbreaks have occurred throughout the Asia-Pacific region, posing a severe global public health threat; however, no specific therapeutic strategy exists for treating EV71-infected children.
Areas Covered:
Five manufacturers have produced inactivated EV71 whole virus vaccines in mainland China, Taiwan, and Singapore, which have completed Phase III (mainland China) and Phase I (Taiwan and Singapore) clinical trials. Various EV71 vaccine candidates are being researched in animal models, including live-attenuated virus vaccine, recombinant VP1 vaccine, VP1-based DNA vaccine, synthetic peptide vaccine and virus-like particle vaccine. In this review, the present situation is summarized, and feasible improvements to the EV71 vaccine are explored.
Expert Opinion:
Although inactivated EV71 vaccines are safe, efficient and elicit strong immune responses to protect adults, children and infants against infection, the quality control of production is critical.
